Seven Springs Wealth Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Seven Springs Wealth Group’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-827	Closed	-$489K	–	65
2022 Q2	$489K	Hold	827	–	–	0.25%	42
2022 Q1	$578K	Hold	827	–	–	0.27%	38
2021 Q4	$522K	Hold	827	–	–	0.24%	40
2021 Q3	$500K	Hold	827	–	–	0.24%	38
2021 Q2	$462K	Buy	+827	New	+$419K	0.2%	46

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Seven Springs Wealth Group's REGN Position: Q3 2022 in Review

Seven Springs Wealth Group sold out of Regeneron Pharmaceuticals (REGN) in Q3 2022, closing a stake of 827 shares — an estimated $489K sold.

Seven Springs Wealth Group first reported a position in REGN in Q2 2021 and held it in 5 quarters. The position peaked at $578K in Q1 2022. 1,080 funds tracked by Wall St. Rank hold REGN as of Q3 2022.

Seven Springs Wealth Group reported no remaining Regeneron Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
Seven Springs Wealth Group sold 827 Regeneron Pharmaceuticals shares in Q3 2022, an estimated $489K.
Seven Springs Wealth Group first reported a position in Regeneron Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Seven Springs Wealth Group's Regeneron Pharmaceuticals position peaked at $578K in Q1 2022.
1,080 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2022.

Based on Seven Springs Wealth Group's 13F filing for Q3 2022, filed 21 Oct 2022.